Host-Microbiome Cross-talk in Oral Mucositis

Overview

Journal J Dent Res

Specialty Dentistry

Date 2016 Apr 8

PMID 27053118

Citations 48

Authors

R M Vasconcelos

N Sanfilippo

B J Paster

A R Kerr

Y Li

L Ramalho

E L Queiroz

B Smith

S T Sonis

P M Corby

Affiliations

Soon will be listed here.

Abstract

Oral mucositis (OM) is among the most common, painful, and debilitating toxicities of cancer regimen-related treatment, resulting in the formation of ulcers, which are susceptible to increased colonization of microorganisms. Novel discoveries in OM have focused on understanding the host-microbial interactions, because current pathways have shown that major virulence factors from microorganisms have the potential to contribute to the development of OM and may even prolong the existence of already established ulcerations, affecting tissue healing. Additional comprehensive and disciplined clinical investigation is needed to carefully characterize the relationship between the clinical trajectory of OM, the local levels of inflammatory changes (both clinical and molecular), and the ebb and flow of the oral microbiota. Answering such questions will increase our knowledge of the mechanisms engaged by the oral immune system in response to mucositis, facilitating their translation into novel therapeutic approaches. In doing so, directed clinical strategies can be developed that specifically target those times and tissues that are most susceptible to intervention.

Citing Articles

Recent nanoengineered therapeutic advancements in sepsis management.

Liu L, Li L, Wang T, Li Z, Yan B, Tan R Front Bioeng Biotechnol. 2024; 12:1495277.

PMID: 39703795 PMC: 11655211. DOI: 10.3389/fbioe.2024.1495277.

Radiation-induced rhinosinusitis: Mechanism research and clinical progress review.

Zheng C, Yu L, Jiang Y World J Otorhinolaryngol Head Neck Surg. 2024; 10(4):324-332.

PMID: 39677057 PMC: 11634722. DOI: 10.1002/wjo2.134.

Gold nanoparticles as innovative therapeutics for oral mucositis: A review of current evidence.

Choudhury M, Brunton P, Dias G, Schwass D, Meledandri C, Ratnayake J Drug Deliv Transl Res. 2024; .

PMID: 39625578 DOI: 10.1007/s13346-024-01748-x.

Microbiome and Communication Disorders: A Tutorial for Clinicians.

Venkatraman A, Davis R, Tseng W, Thibeault S J Speech Lang Hear Res. 2024; 68(1):148-163.

PMID: 39572259 PMC: 11842070. DOI: 10.1044/2024_JSLHR-24-00436.

Probiotics in the management of radiation-induced oral mucositis.

Li Y, Li Z, Zheng S, Xu X Front Cell Infect Microbiol. 2024; 14:1477143.

PMID: 39359935 PMC: 11445617. DOI: 10.3389/fcimb.2024.1477143.

References

Elad S, Epstein J, Raber-Durlacher J, Donnelly P, Strahilevitz J . The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. J Oral Pathol Med. 2011; 41(3):229-34. DOI: 10.1111/j.1600-0714.2011.01094.x. View

Ames N, Sulima P, Ngo T, Barb J, Munson P, Paster B . A characterization of the oral microbiome in allogeneic stem cell transplant patients. PLoS One. 2012; 7(10):e47628. PMC: 3483166. DOI: 10.1371/journal.pone.0047628. View

Chavan R, Pannaraj P, Luna R, Szabo S, Adesina A, Versalovic J . Significant morbidity and mortality attributable to rothia mucilaginosa infections in children with hematological malignancies or following hematopoietic stem cell transplantation. Pediatr Hematol Oncol. 2013; 30(5):445-54. DOI: 10.3109/08880018.2013.783893. View

Blijlevens N, Logan R, Netea M . The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis. J Antimicrob Chemother. 2009; 63 Suppl 1:i36-40. DOI: 10.1093/jac/dkp081. View

Sturm A, Rilling K, Baumgart D, Gargas K, Abou-Ghazale T, Raupach B . Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun. 2005; 73(3):1452-65. PMC: 1064918. DOI: 10.1128/IAI.73.3.1452-1465.2005. View

Villa A, Sonis S . Mucositis: pathobiology and management. Curr Opin Oncol. 2015; 27(3):159-64. DOI: 10.1097/CCO.0000000000000180. View

Srikrishna G, Freeze H . Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009; 11(7):615-28. PMC: 2697348. DOI: 10.1593/neo.09284. View

Wijers O, Levendag P, Harms E, Schmitz P, Hendriks W, Wilims E . Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys. 2001; 50(2):343-52. DOI: 10.1016/s0360-3016(01)01444-4. View

Thomas C, Versalovic J . Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes. 2010; 1(3):148-63. PMC: 2909492. DOI: 10.4161/gmic.1.3.11712. View

10.

Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S . Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014; 40(5):409-21. DOI: 10.1111/apt.12878. View

11.

Sonis S . New thoughts on the initiation of mucositis. Oral Dis. 2010; 16(7):597-600. DOI: 10.1111/j.1601-0825.2010.01681.x. View

12.

Laheij A, de Soet J, von dem Borne P, Kuijper E, Kraneveld E, van Loveren C . Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients. Support Care Cancer. 2012; 20(12):3231-40. PMC: 3480583. DOI: 10.1007/s00520-012-1463-2. View

13.

Corby P, Biesbrock A, Bartizek R, Corby A, Monteverde R, Ceschin R . Treatment outcomes of dental flossing in twins: molecular analysis of the interproximal microflora. J Periodontol. 2008; 79(8):1426-33. DOI: 10.1902/jop.2008.070585. View

14.

Stringer A . Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients. 2013; 5(5):1488-99. PMC: 3708331. DOI: 10.3390/nu5051488. View

15.

Pedroso S, Vieira A, Bastos R, Oliveira J, Cartelle C, Arantes R . Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology (Reading). 2015; 161(10):1950-1960. DOI: 10.1099/mic.0.000149. View

16.

Hu Y, Shao Z, Wang Q, Jiang Y, Ma R, Tang Z . Exploring the dynamic core microbiome of plaque microbiota during head-and-neck radiotherapy using pyrosequencing. PLoS One. 2013; 8(2):e56343. PMC: 3578878. DOI: 10.1371/journal.pone.0056343. View

17.

Limaye S, Haddad R, Cilli F, Sonis S, Colevas A, Brennan M . Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013; 119(24):4268-76. DOI: 10.1002/cncr.28365. View

18.

Wang Y, Zhou X, Xu X . Oral microbiota: an overlooked etiology for chemotherapy-induced oral mucositis?. J Formos Med Assoc. 2013; 114(4):297-9. DOI: 10.1016/j.jfma.2013.10.014. View

19.

Reynolds M, Minah G, Peterson D, Weikel D, Williams L, Overholser C . Periodontal disease and oral microbial successions during myelosuppressive cancer chemotherapy. J Clin Periodontol. 1989; 16(3):185-9. DOI: 10.1111/j.1600-051x.1989.tb01638.x. View

20.

Spijkervet F, Van Saene H, Van Saene J, Panders A, Vermey A, Mehta D . Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol. 1991; 46(3):167-73. DOI: 10.1002/jso.2930460309. View